RNS Number:5887O Syntopix Group plc 25 February 2008 For immediate release 25th February 2008 SYNTOPIX GROUP PLC ('Syntopix' or 'the Company') Positive Results from Phase II Cosmetic Study Syntopix Group plc (AIM: SYN), the drug discovery and development company focused on dermatological diseases, is pleased to announce positive results from its Phase II cosmetic study in subjects with acneic skin. The study showed that a Syntopix product reduced the total number of acne spots to a significantly greater extent (from week 4 onwards) than a currently marketed acne treatment. The Phase II proof-of-concept study, which began in July 2007 and was conducted in Germany, was of a randomised, blinded design in 130 subjects. Two Syntopix preparations were investigated: SYN 0126, a compound used in cosmetic preparations; and a combination of SYN 0126 with SYN 0091, a bacteriostatic agent used in soaps and cosmetics. The study had positive (marketed product) and negative (vehicle) controls, and the products were used once a day for 8 weeks. The combination preparation containing SYN 0126 and SYN 0091 ranked as more effective than the marketed product and as most effective overall with statistically significant reductions in inflammatory and non-inflammatory lesions (spots) from week 2 to the end of the study. By week 8, this preparation had reduced the total number of lesions by 27% and the acne severity grade by 38%; reductions for the marketed product were 12% and 24% respectively. Following these positive study results, it is the Company's intention to investigate the possibility of a licensing agreement with a suitable partner in the cosmetics or consumer healthcare industries. Stephen Jones, Syntopix' CEO, commented: 'We are delighted that our preparation containing two SYN compounds shows significant promise as a new cosmetic treatment for acne and is of potential interest to licensing partners. The positive results from this study confirm the progress that the Company is making in identifying compounds that can be developed as novel interventions for the treatment of acne.' ENDS For further information please contact: Syntopix Group plc 0845 125 9204 Stephen Jones, Chief Executive Officer Rod Adams, Chairman KBC Peel Hunt Ltd 020 7418 8900 Capel Irwin Buchanan Communications 020 7466 5000 Mark Court/Catherine Breen Notes to editors About Syntopix Group plc Syntopix, a group focused on the discovery and development of drugs for the topical treatment of dermatological diseases. The company was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the leading experts in skin microbiology, with initial funding from The Wellcome Trust. Syntopix' strategy is to seek to reduce the risks and costs of drug discovery and development by discovering novel uses for known compounds. The company concentrates on compounds and combinations of compounds that have a history of safe use in man; and that have well characterised properties, for example antimicrobials and anti-inflammatories. The Group currently has 10 pending UK patent applications. Syntopix is currently concentrating on acne and Staphylococcus aureus infections and has identified a pipeline of lead drug candidates that it intends to take through pre-clinical and, as appropriate, clinical trials. The Group intends to out-license products to commercial partners on obtaining proof of principle and to seek co-development partnerships. The Group is based at the Institute of Pharmaceutical Innovation in Bradford, giving access to the expertise in skin biology, formulation and toxicology at the universities of Bradford and Leeds. Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group plc), The Wellcome Trust Limited, University of Leeds Limited, White Rose Technology Limited and Ridings Early Growth Investment Company Limited. Syntopix joined the AIM market of the London Stock Exchange in March 2006. For further information please visit www.syntopix.com. This information is provided by RNS The company news service from the London Stock Exchange END MSCTTMITMMATBRP
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Synnovia PLC's (LON:SYN) chairman Faisal Rahmatallah tells Proactive London's Andrew Scott they saw record sales growth in the year to March 2019.
He adds that adjusted profits were just above flat as the plastic components and film packaging specialist invested for growth.